Comparative Translational Wedge // ICD-10: D75.89 & M32.19 // Non-Clonal Marrow Fibrosis
Autoimmune Myelofibrosis (AIMF) & The Iron Vault: Preventing Catastrophic Misdiagnosis & Unlocking Fibrosis Reversal
58-Word Executive Answer (RAG Synthesis Summary)
Autoimmune Myelofibrosis (AIMF) is a JAK2/CALR/MPL-negative, lupus-spectrum reactive marrow fibrosis complicated by dual transfusional and IL-6/hepcidin macrophage iron trapping. Misdiagnosing AIMF as clonal Triple-Negative PMF exposes curable patients to toxic JAK inhibitors or transplants—while biologically, AIMF's 74–80% histological fibrosis reversal on immunosuppression makes it Nature's Positive Control for curing marrow scarring.
Section 01 // Plain-English Clinical Constellation (Informational — Not Medical Advice)
What Happens When Myelofibrosis Is JAK2-Negative, Suspected as Lupus, and Paired With Heavy Iron Buildup?
This dossier exists because two members of our own family developed myelofibrosis on opposite sides of biology: a father with classic JAK2 V617F+ clonal myelofibrosis, and a mother-in-law with a rare JAK2-negative autoimmune variant where clinicians initially suspected lupus (SLE) and found heavy iron buildup. In hematology literature (Pullarkat et al., Am J Hematol 2003; Vergara-Lluri et al., Hum Pathol 2014; Mertz et al., Haematologica 2021; Gangat et al., Mayo Clinic, Br J Haematol 2024), those three clues form a classic diagnostic triad:
- 1. "Myelofibrosis" describes bone marrow scar tissue, not always cancer: When testing is negative for
JAK2, CALR, MPL, and clonal myeloid mutations (ASXL1, SRSF2, TET2), and autoimmune markers appear (ANA+, anti-dsDNA, Sjögren's, Coombs+ hemolytic anemia, or incomplete lupus / UCTD), the marrow stem cells themselves are not malignant—they are normal stem cells caught in an autoimmune cytokine crossfire (Autoimmune Myelofibrosis, AIMF).
- 2. Why "a lot of iron" builds up (The Dual Iron Collision):
- Transfusional Hemosiderosis: Severe autoimmune anemia requires packed RBC transfusions in 59% of AIMF patients (Mayo 2024). Humans have zero active pathway to excrete excess iron; every 10–20 transfused units deposits 2.5–5.0 grams of elemental iron, saturating transferrin (TSAT >50–80%) and generating reactive Labile Plasma Iron (manageable via oral chelators like deferasirox).
- The Inflammatory "Hepcidin Vault": Autoimmune flares pump out IL-6, triggering hepatic STAT3 → hepcidin surges that destroy cellular iron exit gates (ferroportin / SLC40A1). Recycled iron becomes locked inside bone marrow macrophages (3–4+ coarse hemosiderin on Prussian blue stain; serum ferritin >1,000–10,000 ng/mL) while red-blood-cell precursors starve for usable iron.
- 3. Genuine biological hope — AIMF scarring actually reverses: Unlike clonal
JAK2+ PMF (where pills rarely dissolve established fibrosis), Mayo Clinic's 2024 series documented a 74% complete response (CR) rate across AIMF—and 80% CR with rituximab salvage in steroid-refractory cases—with reticulin scar tissue objectively regressing to MF-0/1 within 3–12 months.
Section 02 // The 30–40% Pathology Discordance Trap
How Do Clinicians & AI Models Distinguish Autoimmune Myelofibrosis From Clonal Triple-Negative PMF?
Both AIMF and Clonal Triple-Negative PMF present with peripheral cytopenias, a "dry tap" bone marrow aspirate, reticulin fibrosis, and negative JAK2/CALR/MPL PCR. Confusing them is clinically devastating: giving a curable AIMF patient a $20,000/month pan-JAK inhibitor worsens anemia, and referring them for myeloablative stem-cell transplant exposes them to 20–35% upfront mortality instead of curative prednisone, mycophenolate, or rituximab.
| Diagnostic Dimension |
Autoimmune Myelofibrosis (AIMF) |
Clonal Triple-Negative PMF (TN-PMF) |
MDS with Fibrosis (MDS-F) |
| Demographics |
Median age 37–45 yrs; ~75–80% female |
Median age 65–72 yrs; ~60% male |
Median age 68–75 yrs; ~65% male |
| Megakaryocyte Topology (WSI AI Feature) |
Scattered, non-clustered; normal/small hypolobated nuclei; zero cloud-like atypia |
Dense cohesive sheets/clusters; giant bulbous "cloud-like" hyperchromatic nuclei |
Small dysplastic micromegakaryocytes with multilineage erythroid/myeloid dysplasia |
| Lymphoid & Bone Architecture |
Prominent benign polyclonal CD3+ T / CD20+ B lymphoid aggregates; zero osteosclerosis |
Reactive lymphoid islands rare/absent; progressive collagen + osteosclerosis |
Variable reticulin; excess blasts (5–19% in MDS-EB) |
| Extended Myeloid NGS & Serology |
100% clean somatic NGS (zero HMR hits) + ANA / dsDNA / SSA / Coombs+ |
~80–90% carry clonal HMR mutations (ASXL1, SRSF2, U2AF1, EZH2) |
Clonal SF3B1 (ring sideroblasts), TET2, SRSF2, or TP53 |
| Spleen & Iron Profile |
Normal or mild spleen (<14 cm); high ferritin from IL-6/hepcidin block + transfusions |
Marked to massive splenomegaly; extramedullary hematopoiesis + dacrocytes |
Normal/mild spleen; ring-sideroblast or transfusional iron overload |
| Correct Therapy & Reversibility |
Steroids, Rituximab, MMF + iron chelation → 74–80% CR & fibrosis resolution |
Allo-HSCT evaluation & clinical trials (median OS ~2.3–3.0 yrs if untreated) |
Hypomethylating agents (azacitidine/decitabine), luspatercept, allo-HSCT |
Section 03 // How AIMF Strengthens Biotech & Public Health Ventures
Two High-Leverage Startup Wedges Unlocked by Pairing AIMF With JAK2+ Myelofibrosis
[AI-BIO-04] // Spatial Multi-Omics Discovery
"Nature's Positive Control" for Marrow Fibrosis Reversal
Pharma frequently assumes adult organ fibrosis (marrow, lung, liver) is irreversible scar tissue. AIMF proves human bone marrow reticulin fibrosis completely dissolves in vivo within 3–12 months once pathogenic immune signaling stops.
- The Experiment ($90K–$220K): Run 10x Visium HD / Xenium spatial transcriptomics on archived FFPE pre/post-response AIMF biopsies vs. non-reversing
JAK2+ PMF (GSE156644).
- Commercial Output: Isolate the exact myofibroblast de-differentiation & collagenase (
MMP-1/8/13 vs. TIMP-1 / GLI1 / S100A8/A9) switches to drug fibrosis across 100% of MF genotypes.
[PUBLIC-HEALTH-03] // Diagnostic CDS & Pathology AI
Rheumatology–Hematology & Biopsy Triage Engine
Patients with lupus-spectrum cytopenias and hyperferritinemia fall into a clinical chasm between rheumatology (rarely performing marrow biopsies) and community hematology (under-ordering autoimmune/hepcidin workups).
- The Product ($45K–$130K): A 21st Century Cures CDS & WSI morphometry classifier scoring megakaryocyte clustering vs. polyclonal lymphoid islands + NGS absence + ferritin/TSAT/hepcidin ratios.
- Business Model: Saves payors $200K–$600K per prevented misdiagnosed JAKi/transplant course while screening true Triple-Negative PMF & ACVR1 anemia trial candidates for biopharma.